News
RSV Vaccination - Arexvy
Respiratory syncytial virus (RSV) is a common cause of respiratory illness in infants and young children, as well as older adults. Each season, RSV causes substantial morbidity and mortality in older adults, including lower respiratory tract infection, hospitalisation, and death.
Arexvy is a vaccine that causes the immune system to produce RSV antibodies. It includes an adjuvant which is a component that enhances the immune response to the vaccination. Arexvy became available in New Zealand in May 2024. It is not yet funded on the immunisation schedule, but is available for purchase.
It is currently (2026) approved for use in adults 60 years and older, and for adults 50-59 years of age who are at increased risk of RSV disease. In general, it is most recommended for adults aged 75 years and older, and adults aged 50 years and older with multiple risk factors, including
- Chronic cardiac, neurological, neuromuscular, respiratory conditions
- Haematological conditions
- Diabetes with complications
- Chronic liver or kidney disorders
- Moderate or severe immunocompromise
- High degree of frailty
- Living in a nursing home or long term care facility
A single dose of Arexvy is highly effective at preventing serious respiratory illness from RSV, and protection is expected to last for up to three years. It is anticipated that adults may need additional doses of RSV vaccine in the future, but ideal revaccination timing is not yet known.
Further information can be reviewed via the following links:
Please email our nursing team at nurse@mtedenvillagedoctors.co.nz if you wish to purchase an Arexvy vaccination.